arrow_back Back Filing freshness 10-Q Q2 FY2026 SEC EDGAR

Akebia Therapeutics, Inc.

AKBA
$0.43 ▼ -0.26 (-38.25%) at close
Healthcare ·Pharmaceutical Preparations ·USPharmaceutical Preparations
56 Visible periods
31 Metrics
Peer-ranked Benchmarks
Price Chart
38
Health
Weak
Bearish
auto_awesome

Analytical Summary

Akebia Therapeutics, Inc. faces fundamental challenges with weakness in Debt to Equity. The fundamentals warrant careful consideration of downside risks.

Market Cap $115.9M
Dividend Yield —
Revenue Growth -21.4% ↘
Op. Margin -12.9% ↘
ROIC -8.5% ↘
FCF / Share $0.01 ↗
Trailing P/E —
Price / Book 4.7x
FCF Yield 2.1%
Debt / Equity 1.98
info Valuation on last close. End-of-day price, Nov 5, 2026.

56-Year Financial Trajectory

Quarterly
Metric Value Trend Year over Year Percentile
Revenue Total top-line sales
$49.13M
↓ -21.4% —
Net Income Profit after all expenses
$-9.05M
— 0.0% —
Operating Margin Operating profit as % of sales
-12.9%
↓ -46.8% 56th
FCF / Share Free cash flow per share
$0.01
↑ +111.4% —
Long-Term Debt Long-term obligations
$49.56M
↑ +1.4% —
trending_up

Bullish Indicators

  • No bullish signals detected.
warning

Bearish Risks

  • Debt to EquityDebt to Equity is concerning (bottom quartile)

Health Breakdown

Profitability ↑
58
Returns ↑
30
Financial Health ↑
44
Cash Quality
1

bar_chart Data from SEC EDGAR XBRL filings

Synced 5 days ago 15 years · 56 quarters